JAZZ Stock Recent News

The average of price targets set by Wall Street analysts indicates a potential upside of 51.8% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Data from a late-stage study showed that Jazz's Zepzelca, combined with Roche's Tecentriq, improved survival rates in certain patients with small-cell lung cancer.

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. The partial legal win against Avadel helps protect Jazz's market position in idiopathic hypersomnia through 2036 and Jazz should also receive royalties on net sales of Lumryz. The unexpected phase 3 trial win of Zepzelca in combination with Tecentriq could add more than $400-500 million in annual net sales by the end of the decade.

Jazz Pharmaceuticals plc JAZZ revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG's RHHBY atezolizumab (Tecentriq) compared to atezolizumab alone when administered as a maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab.

Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC DUBLIN , Oct. 15, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of Zepzelca and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone.

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab.

Here, we discuss some reasons why buying JAZZ stock now may turn out to be a prudent move.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–es ti mated overall survival (OS) of 59% at 30 months DUBLIN , Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA).